pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

transcenta PRESS RELEASE ARCHIVE

Aug 15, 2023

Transcenta to Present Three Study Results at ESMO 2023 USA - English APAC - English

Jul 30, 2023

Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density USA - English APAC - English

Jul 7, 2023

Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001) USA - English APAC - English

Jun 30, 2023

Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023 USA - English APAC - English

Jun 5, 2023

Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting USA - English APAC - English

Jun 2, 2023

Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference. USA - English APAC - English

May 16, 2023

Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density USA - English APAC - English

May 8, 2023

Transcenta to Present Two Clinical Trial Progress at ASCO 2023 USA - English APAC - English

Mar 29, 2023

Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer

Mar 22, 2023

Transcenta to Present Two Preclinical Studies at AACR 2023 USA - English APAC - English

Mar 22, 2023

Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors USA - English APAC - English

Jan 17, 2023

Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

Jan 3, 2023

Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Nov 10, 2022

Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting

Nov 9, 2022

Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call and TST003 data release and pipeline development progress update

Oct 24, 2022

Transcenta To Present First-In-Class TST003 Antibody Program at the 10th TEMTIA Meeting

Oct 24, 2022

Transcenta to Participate in Four Upcoming Conferences

Oct 13, 2022

Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting

Oct 4, 2022

Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy

Sep 14, 2022

Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Sep 12, 2022

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

Aug 7, 2022

Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Jul 27, 2022

Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022

Jun 27, 2022

Transcenta was Selected to Present the Preclinical Data of TST004 at the 2022 ISN Frontiers Meetings of Complement Related Kidney Diseases

Jun 1, 2022

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022

May 30, 2022

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists

Apr 28, 2022

Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting

Apr 28, 2022

Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis

Apr 21, 2022

Transcenta Successfully Passed the Audit of EU Qualified Person for the Manufacturing of TST001

Mar 30, 2022

Transcenta Announces Presentation of Preclinical Data of TST005 at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 21, 2022

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer

Mar 9, 2022

Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress

Feb 27, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

Jan 12, 2022

Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

Dec 16, 2021

Transcenta Announces the Appointment of Daniel Weng as CFO

Sep 26, 2021

Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002

Aug 17, 2021

Transcenta Held Investigator Meeting and Initiated Phase IIa Clinical Trial of Claudin18.2 Monoclonal Antibody TST001 with First Patient Dosed Successfully

Jul 28, 2021

Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction

Jul 22, 2021

908 Devices and Transcenta’s Joint Innovation Partnership Accelerates Biopharma Development

Jul 14, 2021

Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005

Jul 6, 2021

Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002

Jul 2, 2021

Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer

Jun 1, 2021

Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody

May 19, 2021

Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies

May 13, 2021

Transcenta Announces Updated Clinical Data from Phase I Study of pH-Dependent PD-L1 Antibody MSB2311 to Be Presented at the 2021 ASCO Annual Meeting

Apr 20, 2021

Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005

Apr 18, 2021

Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer

Apr 15, 2021

Transcenta Announced Presentation of Preclinical Data of TST005 at 2021 AACR Virtual Annual Meeting

Mar 23, 2021

Transcenta Announces Appointments of Dr. Xichen Zhang as Senior Vice President of Manufacturing and Dr. Steven Yu as Senior Vice President of DMPK and Translational Science

Mar 16, 2021

Transcenta Continues to Push the Boundary of Cell Culture Productivity by Achieving > 6 g/L PER Day Volumetric Productivity in Continuous Perfusion Platform

Feb 10, 2021

Transcenta Holding Announces Appointment of Dr. Michael Shi as Executive Vice President, Head of Global RandD and Chief Medical Officer

Dec 22, 2020

Transcenta Closes $105 Million in Crossover Financing

Sep 15, 2020

Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy

Sep 7, 2020

Transcenta Holding Announces Appointment of Dr. Charlie Qi as Senior Vice President of Global Clinical Development

Aug 31, 2020

Transcenta Announces First Patient Dosed in Phase I China Trial of Claudin18.2 Targeting Monoclonal Antibody TST001

Jul 1, 2020

Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US

May 27, 2020

Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies

May 21, 2020

Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II

Apr 20, 2020

Transcenta Received IND Clearance from FDA for Initiating Clinical Trials for its Novel Humanized Claudin 18.2 Monoclonal Antibody TST001

Apr 1, 2020

908 Devices and Transcenta Expand Joint Innovation Partnership

Feb 18, 2020

Transcenta Achieves Major Milestone in Continuous Perfusion Cell Culture Platform to Provide Industry Leading Productivity and Speed to Manufacturing

Jan 20, 2020

Transcenta Announces Acceptance by NMPA of IND Application of a Novel Humanized Claudin 18.2 Monoclonal Antibody

Jan 8, 2020

Transcenta Holding Secures $100 Million Series B Plus Financing

Jan 6, 2020

Transcenta to Present at the 38th Annual J.P. Morgan Healthcare Conference

Mar 28, 2019

Transcenta Holding Announces Licensing Agreement with Lilly

Mar 11, 2019

Transcenta Holding announces appointment of Dr. Yi Gu as Senior Vice President and Head of Research

Jan 1, 2019

MabSpace Biosciences Merged with HJB to Form Transcenta Holding, a Fully Integrated Leading Global Biotherapeutics Company

Google Analytics Alternative